[go: up one dir, main page]

MX2019002057A - Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. - Google Patents

Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.

Info

Publication number
MX2019002057A
MX2019002057A MX2019002057A MX2019002057A MX2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A MX 2019002057 A MX2019002057 A MX 2019002057A
Authority
MX
Mexico
Prior art keywords
solid forms
cenicriviroc mesylate
processes
cenicriviroc
mesylate
Prior art date
Application number
MX2019002057A
Other languages
English (en)
Inventor
Ian Cooper Martin
Phiasivongsa Pasit
Kay Sharp Emma
Original Assignee
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tobira Therapeutics Inc filed Critical Tobira Therapeutics Inc
Publication of MX2019002057A publication Critical patent/MX2019002057A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a formas sólidas de mesilato de cenicriviroc, métodos para su preparación, composiciones farmacéuticas de estas y métodos para su uso.
MX2019002057A 2016-08-31 2017-08-30 Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc. MX2019002057A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662382153P 2016-08-31 2016-08-31
PCT/US2017/049400 WO2018045043A1 (en) 2016-08-31 2017-08-30 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate

Publications (1)

Publication Number Publication Date
MX2019002057A true MX2019002057A (es) 2019-11-18

Family

ID=61241572

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002057A MX2019002057A (es) 2016-08-31 2017-08-30 Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.

Country Status (13)

Country Link
US (1) US10301287B2 (es)
EP (1) EP3506896A4 (es)
JP (2) JP2019526628A (es)
KR (1) KR20190057066A (es)
CN (1) CN110167550A (es)
AU (1) AU2017321594A1 (es)
BR (1) BR112019003987A2 (es)
CA (1) CA3034606A1 (es)
MX (1) MX2019002057A (es)
RU (1) RU2019109019A (es)
SG (1) SG11201901438VA (es)
TW (1) TW201823235A (es)
WO (1) WO2018045043A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019238041A1 (zh) * 2018-06-12 2019-12-19 南京明德新药研发有限公司 一种丙烯酰胺类化合物的晶型及其制备方法
US11613670B2 (en) * 2018-06-18 2023-03-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US20210379824A1 (en) * 2018-06-18 2021-12-09 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245589A1 (en) 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
US11591486B2 (en) 2018-06-19 2023-02-28 Hewlett-Packard Development Company, L.P. Three-dimensional printing
WO2019245534A1 (en) * 2018-06-19 2019-12-26 Hewlett-Packard Development Company, L.P. Three-dimensional printing
CN112638995B (zh) * 2018-08-31 2024-03-19 赢创运营有限公司 制备聚合物粉末的方法
WO2021133811A1 (en) 2019-12-26 2021-07-01 Teva Pharmaceuticals International Gmbh Solid state forms of cenicriviroc and process for preparation thereof
MX2022014523A (es) 2020-05-22 2022-12-13 Medshine Discovery Inc Derivado de piridina y aplicacion del mismo.
JP7374372B2 (ja) * 2021-02-22 2023-11-06 旭化成株式会社 セルロースナノファイバーを含む組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265270A (ja) 1986-05-13 1987-11-18 Zeria Shinyaku Kogyo Kk 新規イミダゾ−ル誘導体およびそれらを有効成分とする抗潰瘍剤
CN1151744A (zh) 1994-07-04 1997-06-11 武田药品工业株式会社 膦酸化合物及其制备和应用
WO1999032100A2 (en) 1997-12-19 1999-07-01 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
CA2337307A1 (en) 1998-08-20 2000-03-02 Osamu Nishimura Quaternary ammonium salts and their use
AU6870600A (en) 1999-09-06 2001-04-10 Takeda Chemical Industries Ltd. Process for the preparation of 2,3-dihydroazepine compounds
EP2206702B1 (en) 2001-08-08 2011-12-28 Tobira Therapeutics, Inc. Bicyclic compound, production and use thereof
CA2479071A1 (en) 2002-03-12 2003-09-18 Hiroyuki Tawada Process for producing optically active sulfoxide derivative
CA2562388A1 (en) 2004-03-24 2005-09-29 Takeda Pharmaceutical Company Limited Emulsion-stabilized preparation
JP2007269628A (ja) * 2004-05-28 2007-10-18 Takeda Chem Ind Ltd 医薬化合物の結晶
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EA201390726A1 (ru) 2010-11-18 2014-06-30 Йельский Университет Бифункциональные молекулы с активностью, привлекающей антитела и ингибирующей проникновение вируса иммунодефицита человека
EP2846788A1 (en) * 2012-05-11 2015-03-18 Akron Molecules AG Use of compounds for the treatment of pain
KR20160013068A (ko) 2013-05-15 2016-02-03 토비라 쎄라퓨틱스, 인크. 세니크리비록 조성물 및 이들을 만들고 이용하는 방법
MX2016012262A (es) 2014-03-21 2017-01-06 Tobira Therapeutics Inc Cenicriviroc para el tratamiento de fibrosis.
WO2015187663A1 (en) 2014-06-02 2015-12-10 Tobira Therapeutics, Inc. Cenicriviroc for the treatment of hiv-2 infection
US10526349B2 (en) 2014-12-23 2020-01-07 Tobira Therapeutics, Inc. Process of making cenicriviroc and related analogs

Also Published As

Publication number Publication date
KR20190057066A (ko) 2019-05-27
BR112019003987A2 (pt) 2019-05-28
CA3034606A1 (en) 2018-03-08
RU2019109019A3 (es) 2021-08-23
WO2018045043A1 (en) 2018-03-08
CN110167550A (zh) 2019-08-23
TW201823235A (zh) 2018-07-01
RU2019109019A (ru) 2020-10-01
EP3506896A4 (en) 2020-08-26
US10301287B2 (en) 2019-05-28
AU2017321594A1 (en) 2019-04-18
SG11201901438VA (en) 2019-03-28
US20180057481A1 (en) 2018-03-01
EP3506896A1 (en) 2019-07-10
JP2019526628A (ja) 2019-09-19
JP2022137223A (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (es) Polinucleotidos moduladores.
MX2019002057A (es) Formas solidas de mesilato de cenicriviroc y procesos para elaborar formas sólidas de mesilato de cenicriviroc.
MX2019001313A (es) Composiciones farmaceuticas.
PL3668937T3 (pl) Kompozycje i zastosowania Z-1-chloro-2,3,3,3-tetrafluoroprop-1-enu
WO2016011222A3 (en) Circular polynucleotides
WO2016011306A3 (en) Terminal modifications of polynucleotides
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
MX2017004808A (es) Combinaciones que comprenden siponimod y laquinimod para el tratamiento de la esclerosis multiple.
IL297652B2 (en) Compositions containing methylphenidate prodrugs, processes for their preparation and use
MX2018008424A (es) Compuestos antiproliferativos y sus composiciones farmaceuticas y usos.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019005855A (es) Formulaciones que se pueden pulverizar.
TR201821116A2 (tr) POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12016501686A1 (en) Pharmaceutical compositions of sitagliptin
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.
IN2014CH00840A (es)
HK1254231A1 (zh) 米托-和厚朴酚化合物及其合成方法和用途
PL3468964T3 (pl) Modulatory soce, ich kompozycje i zastosowania
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,
EP4582145A3 (en) Solid state forms of ixazomib citrate
NZ721832A (en) Solid forms of tenofovir
WO2016033549A3 (en) (17-β)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE